Skip to content

Scailyte closed today their pre-series A financing

Scailyte closed their pre-series A financing round with CHF 3.7 million led by Swisscom Ventures, 4FO ventures, Hemex and Investiere.

Scailyte™ is delighted to welcome investiere as an additional investor just before closing the pre-series A financing round.™

Today, Scailyte closed their pre-series A financing round with CHF 3.7 million led by Swisscom Ventures, joined by 4FO ventures, a private investor, Hemex and Investiere. This pre-series A financing round will allow Scailyte to develop faster their assays in the rapid-emerging single-cell data technology field. The raised capital will be used to further build upon Scailyte’s biomarker and IVD pipeline and for the development of the first clinical applications using single-cell biomarkers.

Scailyte is honored to have investiere among their renowned investor base. The additional financing increases the opportunities for Scailyte to develop in-vitro diagnostics using single-cell technologies and their proprietary single-cell data analysis platform ScaiVision™.

“We are continuously developing and utilizing our data analytics platform ScaiVision™ for biomarker discovery from single-cell data” says Peter Nestorov, CEO of Scailyte AG. “The current version covers all aspects of processing, handling and interpreting single-cell proteomics data (mass and flow cytometry), as well as a core functionality for analysing single-cell transcriptomics data. This allows us to accelerate biomedical discovery and enable the next generation of precision diagnostics. With the support of strong partners like Swisscom Ventures, 4FO and HEMEX, we will continue to grow in the fast-emerging single-cell analysis field, enabling various clinical applications of single-cell data “.

“Scailyte has a strong product pipeline. It includes candidates for biomarkers for Endometriosis and CTCL with a market potential of several hundred million Francs for each of these diagnostics. Furthermore, Scailyte enjoys strong support in the medical expert community” says Susanne Schorsch, Investment Manager at investiere.

investiere provides exclusive access to start-up investments to qualified private and institutional investors. investiere is one of the most active startup investors in Switzerland, backed by business angels as well as ZKB with more than 90 investments.

Scailyte AG was founded in Luzern, Switzerland in July 2017. Scailyte is an ETH Zurich spin-off and is supported by Innosuisse (Swiss Innovation Agency). The company has gained recognition by winning several national and international start-ups competitions and is the beneficiary of significant research grants. Scailyte has a multi-disciplinary team with expertise in Cell biology, Genetics, Artificial Intelligence, Software development, Finance, Marketing and Sales. Scailyte discovers ultrasensitive biomarkers and develops in-vitro diagnostics using single-cell technologies and their proprietary single-cell data analysis platform ScaiVision™. ScaiVision™ offers best-in-class analysis of complex single-cell data to enhance biomedical research, pharmaceutical discovery, and precision diagnostics. Besides developing its own in vitro diagnostic (IVD) applications, Scailyte also offers its biomarker discovery services to companies aiming to complement and enrich their analysis by adding the single-cell perspective.

The ScaiVision™ biomarker discovery platform delivers best-in-class performance for supervised pattern recognition analysis of single-cell data. The performance and clinically relevant application of the core deep learning algorithm of ScaiVision have been validated in several scientific papers and have resulted in patent-pending diagnostic applications. For more information visit www.scailyte.com

ScailyteTM and ScaiVisionTM are registered trademarks proprietary to Scailyte AG.

Recent News

Transforming Healthcare with Unmatched Biomarker Discovery Power

Experience the game-changing convergence of AI and healthcare. Join us on this journey as we transla...

Read more

Recent News

LSX Congress USA 2023

Join Scailyte at the LSX Congress USA in Boston on September 13-14 at the Hynes Convention Centre, B...

Read more

Recent News

Unveiling ScaiVision's Clinical Potential

Embarking on the last leg of our Discovery Potential series, we're delving into ScaiVision's incredi...

Read more

Recent News

ScaiDigest Volume 3: Unveiling Immuno-Oncology's Next Frontier

In Volume 3, our very own Diana Stoycheva takes the helm to explore the fascinating realm of single-...

Read more

Recent News

Revolutionizing Biomarker Discovery: Unlock the Power of Scailyte's AI platform

Dive into the forefront of scientific advancement with Scailyte's groundbreaking AI platform, ScaiVi...

Read more

Recent News

Empowering Precision Healthcare with Unparalleled Discovery Potential

From revealing hidden insights to transforming healthcare, ScaiVision is rewriting the rules of disc...

Read more

Recent News

Accelerating Discoveries with Scailyte's Speed Strength

In the world of clinical research and development, time is of the essence. Our mission at Scailyte i...

Read more

Recent News

Nurturing Wellbeing in Our Workspace: Prioritizing People's Growth

At Scailyte, our commitment to ESG goes beyond numbers. It extends to every individual within our vi...

Read more

Recent News

01 /04

Transforming Healthcare with Unmatched Biomarker Discovery Power

Experience the game-changing convergence of AI and healthcare. Join us on this journey as we transla...

Read more

LSX Congress USA 2023

Join Scailyte at the LSX Congress USA in Boston on September 13-14 at the Hynes Convention Centre, B...

Read more

Recent News

02 /04

Unveiling ScaiVision's Clinical Potential

Embarking on the last leg of our Discovery Potential series, we're delving into ScaiVision's incredi...

Read more

ScaiDigest Volume 3: Unveiling Immuno-Oncology's Next Frontier

In Volume 3, our very own Diana Stoycheva takes the helm to explore the fascinating realm of single-...

Read more

Recent News

03 /04

Revolutionizing Biomarker Discovery: Unlock the Power of Scailyte's AI platform

Dive into the forefront of scientific advancement with Scailyte's groundbreaking AI platform, ScaiVi...

Read more

Empowering Precision Healthcare with Unparalleled Discovery Potential

From revealing hidden insights to transforming healthcare, ScaiVision is rewriting the rules of disc...

Read more

Recent News

04 /04

Accelerating Discoveries with Scailyte's Speed Strength

In the world of clinical research and development, time is of the essence. Our mission at Scailyte i...

Read more

Nurturing Wellbeing in Our Workspace: Prioritizing People's Growth

At Scailyte, our commitment to ESG goes beyond numbers. It extends to every individual within our vi...

Read more

Recent News